Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

德克萨斯州奥斯汀讯——根据向美国证券交易委员会提交的4表格显示，Natera, Inc.（纳斯达克股票代码：NTRA）临床诊断总裁Solomon Moshkevich最近进行了一笔重大的公司股票交易。Moshkevich于2024年12月9日以加权平均价格166.5937美元每股的价格出售了4,858股Natera普通股。此次出售的总价值约为809,312美元。根据 InvestingPro ...

Natera, Inc.（纳斯达克股票代码：NTRA）的董事Chapman Rowan ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

三季度，德鲁肯米勒继续押注“头号重仓股”Natera。 在最新公布的三季度持仓文件中，传奇投资人、杜肯资本创始人斯坦利·德鲁肯米勒（Stanley ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third ...

Natera, Inc. (NASDAQ:NTRA – Get Free Report) has earned an average rating of “Buy” from the seventeen ratings firms that are ...